Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918162 · ClinicalTrials.gov registry record · Phase 2
Perioperative Chemo and Pembrolizumab in Gastric Cancer
A Phase 2 study, sponsored by Gulam Manji.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02918162: Completed Phase 2 study, sponsored by Gulam Manji.
NCT02918162 is a Phase 2 study that has completed, run by Gulam Manji. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02918162, a Phase 2 study, has completed, sponsored by Gulam Manji.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma. The purpose of this study is to determine and evaluate the efficacy of combination therapy with immune checkpoint blockade and chemotherapy used in the perioperative period in eradicating micrometastatic disease; and to compare paired tissue and serum samples (pre-treatment and post-treatment) from individually treated patients to explore the immune effects of combination therapy and predictors of response.
Primary Outcome
Number of subjects with absence of viable tumor on surgical resection specimen as determined by local pathology review.
Interventions
- DRUG Pembrolizumab
- DRUG Standard of care chemotherapy regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-11-25 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
What the finished NCT02918162 record still lists
NCT02918162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02918162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02918162 about?
NCT02918162 is a clinical study titled "Perioperative Chemo and Pembrolizumab in Gastric Cancer". This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma. The purpose of this study is to determine and evaluate the efficacy of combination therapy with immune checkpoint blockade and chemother...
What is the current status of trial NCT02918162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2017-11-25. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT02918162?
The interventions under investigation include: Pembrolizumab (DRUG), Standard of care chemotherapy regimen (DRUG).
Who is sponsoring clinical trial NCT02918162?
This trial is sponsored by Gulam Manji, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02918162's enrollment target sits among peer trials
49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI